Impact of normal-phase gradient elution in chiral chromatography: a novel, robust, efficient and rapid chiral screening procedure

被引:32
作者
de la Puente, ML
White, CT
Rivera-Sagredo, A
Reilly, J
Burton, K
Harvey, G
机构
[1] Lilly SA, European Analyt Technol, Ctr Invest Basica, Alcobendas 28108, Spain
[2] Lilly Res Ctr Ltd, European Analyt Technol, Windlesham GU20 6PH, Surrey, England
关键词
screening; enantiomeric excess; enantiomer separation; gradient elution;
D O I
10.1016/S0021-9673(02)01735-1
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Novel normal-phase gradient systems have been employed for fast high-throughput chiral analyses of Discovery compounds in our research laboratories in Eli Lilly and Company. In this report, we describe an automated screening approach based on gradient elution, in order to achieve accurate enantiomeric excess determinations, and chiral separations when needed, in the shortest possible timeframe. Baseline resolution of enantiomers has been obtained for over 85% of the samples so tested. For the remaining cases, complete enantioseparation by isocratic optimisation is generally achieved in a single shot. This technique has been proven to be robust and is now standard operating procedure at our analytical research laboratories. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:101 / 114
页数:14
相关论文
共 29 条
[1]  
BROWN JR, 1994, PRACTICAL APPROACH C, P57
[2]   Comparative enantioseparation of selected chiral drugs on four different polysaccharide-type chiral stationary phases using polar organic mobile phases [J].
Chankvetadze, B ;
Kartozia, I ;
Yamamoto, C ;
Okamoto, Y .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 27 (3-4) :467-478
[3]   CHROMATOGRAPHIC RESOLUTION OF THE CHIRAL ISOMERS OF SEVERAL BETA-BLOCKERS OVER CELLULOSE TRIS(3,5-DIMETHYLPHENYLCARBAMATE) CHIRAL STATIONARY PHASE [J].
CHING, CB ;
LIM, BG ;
LEE, EJD ;
NG, SC .
CHIRALITY, 1992, 4 (03) :174-177
[4]   THE FDA PERSPECTIVE ON THE DEVELOPMENT OF STEREOISOMERS [J].
DECAMP, WH .
CHIRALITY, 1989, 1 (01) :2-6
[5]   CHIRAL DRUGS - THE FDA PERSPECTIVE ON MANUFACTURING AND CONTROL [J].
DECAMP, WH .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1993, 11 (11-12) :1167-1172
[6]   Reversed-phase liquid chromatographic separation of complex samples by optimizing temperature and gradient time I. Peak capacity limitations [J].
Dolan, JW ;
Snyder, LR ;
Djordjevic, NM ;
Hill, DW ;
Waeghe, TJ .
JOURNAL OF CHROMATOGRAPHY A, 1999, 857 (1-2) :1-20
[7]   Gradient elution in normal-phase high-performance liquid chromatographic systems [J].
Jandera, P .
JOURNAL OF CHROMATOGRAPHY A, 2002, 965 (1-2) :239-261
[8]   Simultaneous optimisation of gradient time, gradient shape and initial composition of the mobile phase in the high-performance liquid chromatography of homologous and oligomeric series [J].
Jandera, P .
JOURNAL OF CHROMATOGRAPHY A, 1999, 845 (1-2) :133-144
[9]   Optimisation of gradient elution in normal-phase high-performance liquid chromatography [J].
Jandera, P .
JOURNAL OF CHROMATOGRAPHY A, 1998, 797 (1-2) :11-22
[10]   Prediction of retention in gradient-elution normal-phase high-performance liquid chromatography with binary solvent gradients [J].
Jandera, P ;
Kucerova, M .
JOURNAL OF CHROMATOGRAPHY A, 1997, 759 (1-2) :13-25